Application Deadline Draws Near for 1999 Charles E. Culpeper Foundation Scholarships in Medical Science

Publication
Article
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

The Charles E. Culpeper Foundation is currently accepting applications for its 1999 Scholarships in Medical Science Program, designed to support the career development of academic physicians

The Charles E. Culpeper Foundation is currently accepting applications for its 1999 Scholarships in Medical Science Program, designed to support the career development of academic physicians.

Up to four awards of $100,000 per year for 3 years will be made to United States medical schools on behalf of candidates who are US citizens or aliens who have been granted permanent US residence (proof required), have received their md degree from a US medical school in 1990 or later (except under extraordinary circumstances), and are judged worthy of support by virtue of the quality of their research proposals. All scientific research relevant to human health is eligible for consideration. No institution may nominate more than one candidate.

In selecting awardees, emphasis will be on identifying young physicians with clear potential for making substantial contributions to science as academic physicians. Since January 1988, 33 physicians have been selected as Charles E. Culpeper Foundation Medical Scholars.

The deadline for applications is August 14, 1998. Awards will be announced in January 1999, for activation on or about July 1, 1999. Application forms and instructions may be obtained on the Web at www.culpeper.org or by contacting the Charles E. Culpeper Foundation at Financial Centre, 695 East Main Street, Stanford, CT 06901-2155 (telephone: 203-975-1240; fax phone: 203-975-1847).

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content